view more news

Epistem will exhibit at the 61st Annual Society of Toxicology (SOT) Meeting

Epistem will be exhibiting at the 61st Annual SOT Meeting and ToxExpo in San Diego, 27-31 March.

read full story

Epistem to exhibit at the American Association for Cancer Research (AACR) Annual Meeting 2022

Epistem is looking forward to exhibiting at the first in-person AACR conference in two years (April 8-13, 2022, New Orleans, LA).

read full story

Epistem receives ISO15189 accreditation

Epistem receives ISO15189:2012 accreditation validating its #COVID19 testing and provides further evidence of the quality to which we operate, having also been GCLP accredited for over 10 years. It also confirms that the tests we perform are carried out to the highest industry standards.

read full story

Epistem licence Hubrecht Organoid Technology to expand preclinical toxicology service portfolio

Epistem Limited has announced the expansion of its in vitro model portfolio by the completion of an agreement with Hubrecht Organoid Technology (HUB) to enable the delivery of an increased range of multi species organoid models. Services are focused on the identification of off target or off tissue intestinal toxicities associated with various therapeutics.

read full story

Epistem completes board line up and launches new NGS service

Epistem Limited, the Manchester based pre-clinical and clinical research services company announces the completion of its Board appointments. Investment from the Foresight group in June 2018 enabled expansion of the research services, the first of which is launched in December 2018 - GCLP compliant Next Generation Sequencing (NGS) services.

read full story